Journal of Cancer Clinical Trials

ISSN: 2577-0535

Open Access

Dean Sittig

Department of Medical Informatics, Northwest Permanente, Portland, OR, USA

  • Mini Review   
    Cannabis-derived Product's Benefits, Drawbacks and Risks as a Cancer Treatment
    Author(s): Dean Sittig*

    Patients especially are interested in the use of cannabis products in oncology. The added value of curative or palliative cancer care as well as the potential risks associated with it is not sufficiently demonstrated, so they remain a topic of debate despite the abundance of available research data. By reviewing the most recent research, our goal is to make a recommendation regarding the place of cannabis products in clinical oncology. The characteristics, quality, and pharmacology of various cannabis products are discussed. For quality that can be trusted and replicated, standardization is essential. In comparison to inhalation and drinking tea the mucosal/sublingual route of administration is preferred. Cannabinoids might repress efflux carriers and medication utilizing catalysts, conceivably prompting pharmacokinetic collaborations with anticancer medication.. Read More»
    DOI: 10.37421/2577-0535.2023.8.203

    Abstract HTML PDF

Google Scholar citation report
Citations: 95

Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report

Journal of Cancer Clinical Trials peer review process verified at publons

Indexed In

arrow_upward arrow_upward